Richard F. Little, M.D.
Dr. Little joined the NCI's Cancer Therapy and Evaluation Program (CTEP) as head of the therapeutics section for Hematologic and AIDS-related Cancers and Hematopoietic Stem Cell in April 2007. His focus is to oversee, review, and coordinate the NCI-sponsored phase III cancer treatment trials in these diseases in an effort to promote practice-changing and definitive clinical trials.
Dr. Little's research interests have focused on immune suppression-related neoplastic disease, investigation of viral targets for oncolytic therapy and immunotherapy, and antiangiogenesis.
Center for Cancer Research
National Cancer Institute
9609 Medical Center Dr., Room 5W426
Rockville, MD 20892-9739